Social Capital Suvretta Holdings Corp. III (DNAC) News
Filter DNAC News Items
DNAC News Results
|Loading, please wait...|
Latest DNAC News From Around the Web
Below are the latest news stories about SOCIAL CAPITAL SUVRETTA HOLDINGS CORP III that investors may wish to consider to help them evaluate DNAC as an investment opportunity.
Palihapitiya's SPAC with ProKidney is expected to close during Q3 of this year.
ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease
Article published online in American Journal of Nephrology; to be included in future print edition WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), today announced the publication of the trial design of its Phase II clinical study of its novel Renal Autologous Cell Therapy (REACT®) in the American Journal of Nephrology. The paper, titled Novel Renal Autologous Cell
SPACs may make a comeback in 2022.
Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney.
SoFi Technologies (SOFI) stock is on the move Tuesday as investors discuss a bank charter for the company and what it could do to the stock.
Roblox (RBLX) stock is on the rise Tuesday despite a lack of news from the gaming and game development platform but lots of chatter.
ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III in a deal that values the combined company at $2.64 billion. The deal, which will take ProKidney public, is expected to provide $825 million in cash proceeds. After the deal closes, which is expected to occur in the third quarter of 2022, the combined company is expected to trade on the Nasdaq under the
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III
WINSTON-SALEM, N.C. & PALO ALTO, Calif., January 18, 2022--ProKidney LP ("ProKidney"), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease ("CKD"), has entered into a definitive agreement to become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III ("SCS") (Nasdaq: DNAC), a special purpose acquisition company. Upon closing, the transaction will accelerate ProKidney’s mission to change the lives of tens of mill
Social Capital Suvretta Holdings Corp. III Announces Pricing of Upsized $220,000,000 Initial Public Offering
PALO ALTO, Calif., June 30, 2021--Social Capital Suvretta Holdings Corp. III (the "Company") announced today that it has priced its upsized initial public offering of 22,000,000 Class A ordinary shares at $10.00 per share. The Class A ordinary shares will be listed on the Nasdaq Capital Market and trade under the ticker symbol "DNAC" beginning June 30, 2021.